These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39121598)

  • 1. Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study.
    Zeineddine M; Al-Hajje A; Salameh P; Massouh J; Saab G; Al-Roughani R; Ahmed SF; Al-Mahdawi A; Shalaby N; Inshasi J; Sahraian MA; Gouider R; Mrabet S; Al-Khabouri J; Shayganneja V; Chentouf A; Boumediene F; Yamout B
    Mult Scler Relat Disord; 2024 Oct; 90():105790. PubMed ID: 39121598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.
    Louapre C; Collongues N; Stankoff B; Giannesini C; Papeix C; Bensa C; Deschamps R; Créange A; Wahab A; Pelletier J; Heinzlef O; Labauge P; Guilloton L; Ahle G; Goudot M; Bigaut K; Laplaud DA; Vukusic S; Lubetzki C; De Sèze J; ; Derouiche F; Tourbah A; Mathey G; Théaudin M; Sellal F; Dugay MH; Zéphir H; Vermersch P; Durand-Dubief F; Françoise R; Androdias-Condemine G; Pique J; Codjia P; Tilikete C; Marcaud V; Lebrun-Frenay C; Cohen M; Ungureanu A; Maillart E; Beigneux Y; Roux T; Corvol JC; Bordet A; Mathieu Y; Le Breton F; Boulos DD; Gout O; Guéguen A; Moulignier A; Boudot M; Chardain A; Coulette S; Manchon E; Ayache SS; Moreau T; Garcia PY; Kumaran D; Castelnovo G; Thouvenot E; Taithe F; Poupart J; Kwiatkowski A; Defer G; Derache N; Branger P; Biotti D; Ciron J; Clerc C; Vaillant M; Magy L; Montcuquet A; Kerschen P; Coustans M; Guennoc AM; Brochet B; Ouallet JC; Ruet A; Dulau C; Wiertlewski S; Berger E; Buch D; Bourre B; Pallix-Guiot M; Maurousset A; Audoin B; Rico A; Maarouf A; Edan G; Papassin J; Videt D
    JAMA Neurol; 2020 Sep; 77(9):1079-1088. PubMed ID: 32589189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
    Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
    Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity.
    Simpson-Yap S; Pirmani A; Kalincik T; De Brouwer E; Geys L; Parciak T; Helme A; Rijke N; Hillert JA; Moreau Y; Edan G; Sharmin S; Spelman T; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton RM; Salter A; Bebo B; Van der Walt A; Butzkueven H; Ozakbas S; Boz C; Karabudak R; Alroughani R; Rojas JI; van der Mei IA; Sciascia do Olival G; Magyari M; Alonso RN; Nicholas RS; Chertcoff AS; de Torres AZ; Arrambide G; Nag N; Descamps A; Costers L; Dobson R; Miller A; Rodrigues P; Prčkovska V; Comi G; Peeters LM
    Neurol Neuroimmunol Neuroinflamm; 2022 Nov; 9(6):. PubMed ID: 36038263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies.
    Smith TE; Madhavan M; Gratch D; Patel A; Saha V; Sammarco C; Rimler Z; Zuniga G; Gragui D; Charvet L; Cutter G; Krupp L; Kister I; Ryerson LZ
    Mult Scler Relat Disord; 2022 Apr; 60():103735. PubMed ID: 35398713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
    Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
    CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis.
    Januel E; Hajage D; Labauge P; Maillart E; De Sèze J; Zephir H; Pelletier J; Guilloton L; Bensa C; Heinzlef O; Casez O; Biotti D; Bourre B; Vukusic S; Maurousset A; Berger E; Laplaud D; Lebrun-Frénay C; Dubessy AL; Branger P; Thouvenot E; Clavelou P; Sellal F; Manchon E; Moreau T; Papeix C; Tubach F; Louapre C
    JAMA Netw Open; 2023 Jun; 6(6):e2319766. PubMed ID: 37351881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
    Smith JB; Gonzales EG; Li BH; Langer-Gould A
    JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis.
    Salter A; Fox RJ; Newsome SD; Halper J; Li DKB; Kanellis P; Costello K; Bebo B; Rammohan K; Cutter GR; Cross AH
    JAMA Neurol; 2021 Jun; 78(6):699-708. PubMed ID: 33739362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 in ocrelizumab-treated people with multiple sclerosis.
    Hughes R; Whitley L; Fitovski K; Schneble HM; Muros E; Sauter A; Craveiro L; Dillon P; Bonati U; Jessop N; Pedotti R; Koendgen H
    Mult Scler Relat Disord; 2021 Apr; 49():102725. PubMed ID: 33482590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.
    Sharifian-Dorche M; Sahraian MA; Fadda G; Osherov M; Sharifian-Dorche A; Karaminia M; Saveriano AW; La Piana R; Antel JP; Giacomini PS
    Mult Scler Relat Disord; 2021 May; 50():102800. PubMed ID: 33578206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France.
    Sormani MP; Salvetti M; Labauge P; Schiavetti I; Zephir H; Carmisciano L; Bensa C; De Rossi N; Pelletier J; Cordioli C; Vukusic S; Moiola L; Kerschen P; Radaelli M; Théaudin M; Immovilli P; Casez O; Capobianco M; Ciron J; Trojano M; Stankoff B; Créange A; Tedeschi G; Clavelou P; Comi G; Thouvenot E; Battaglia MA; Moreau T; Patti F; De Sèze J; Louapre C; ;
    Ann Clin Transl Neurol; 2021 Aug; 8(8):1738-1744. PubMed ID: 34240579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.
    Holroyd KB; Healy BC; Conway S; Houtchens M; Bakshi R; Bhattacharyya S; Bose G; Galetta K; Kaplan T; Severson C; Singhal T; Stazzone L; Zurawski J; Polgar-Turcsanyi M; Saxena S; Paul A; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2022 Nov; 67():104079. PubMed ID: 35952457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East.
    Alroughani R; Inshasi J; Al-Hashel J; Alkhaboury J; Alsalti A; Al Suwaidi R; Hassino LH; Farouk Ahmed S
    J Clin Neurosci; 2022 May; 99():311-316. PubMed ID: 35339046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
    Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.
    Arrambide G; Llaneza-González MÁ; Costa-Frossard França L; Meca-Lallana V; Díaz EF; Moreno-Torres I; García-Domínguez JM; Ortega-Suero G; Ayuso-Peralta L; Gómez-Moreno M; Sotoca-Fernández JJ; Caminero-Rodríguez AB; Rodríguez de Antonio LA; Corujo-Suárez M; Otano-Martínez MA; Pérez-Miralles FC; Reyes-Garrido V; Ayuso-Blanco T; Balseiro-Gómez JJ; Muñoz-Pasadas M; Pérez-Molina I; Arnal-García C; Domingo-Santos Á; Guijarro-Castro C; Íñiguez-Martínez C; Téllez Lara N; Castellanos-Pinedo F; Castillo-Triviño T; Cerdán-Santacruz DM; Pérez-Sempere Á; Torres BS; Álvarez de Arcaya A; Costa-Arpín E; Durán-Ferreras E; Fragoso-Martínez M; González-Platas M; Landete Pascual L; Millán-Pascual J; Oreja-Guevara C; Meca-Lallana JE
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34168057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.